OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy – a subsidiary of Hy-Vee, Inc. – announces today that it has begun administering the FDA-approved infusion treatment bamlanivimab (BAM) to ...
The combination therapy reduced the risk of hospitalization or death by 70%. Data from a phase 3 trial investigating Lilly’s severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results